Rigel Pharmaceuticals Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio16.95
Forward P/E17.39
P/S Ratio1.652.182.243.275.45
P/B Ratio90.11-8.83-19.0414.9217.38
Price/Tangible Book14.9217.38
Price/FCF9.4386.30
Price/OCF9.4177.09
Enterprise Value Ratios
EV/Revenue1.872.542.332.905.15
EV/EBITDA12.69
EV/EBIT13.86
EV/FCF10.6776.67
Profitability & Returns
Return on Equity (ROE)-6.99%-0.56%-0.68%
Return on Assets (ROA)0.11%-0.11%-0.24%-0.09%-0.14%
Return on Invested Capital (ROIC)1.04%-1.25%-9.32%-3.13%-7.40%
Return on Capital Employed (ROCE)0.24%-0.34%-0.85%-0.19%-0.42%
Leverage & Solvency Ratios
Debt/Equity30.40-3.64-6.453.001.15
Debt/EBITDA3.68
Debt/FCF3.1817.38
Liquidity Ratios
Current Ratio2.131.861.782.432.18
Quick Ratio1.881.641.512.211.79
Efficiency Ratios
Asset Turnover1.270.920.771.000.84
Inventory Turnover5.492.765.1710.8212.21
Yield & Distribution Ratios
Earnings Yield0.06%-0.10%-0.23%-0.04%-0.05%
FCF Yield0.11%-0.02%-0.29%0.01%-0.09%
Buyback Yield-0.02%-0.02%0.00%-0.01%-0.01%